Orilissa, also known by its generic name elagolix, is a medication used to manage pain associated with endometriosis [1]. Its efficacy is demonstrated through clinical trials that assess pain reduction in patients [2][3].
How effective is Orilissa for endometriosis pain?
Clinical studies have shown Orilissa to be effective in reducing both menstrual pain and non-menstrual pelvic pain in women with endometriosis [2][3]. For instance, the ELAN trial indicated significant improvements in pain scores for participants treated with Orilissa [3]. Another study, the ELSA trial, also reported reductions in menstrual pain [2].
What are the different strengths and dosages of Orilissa?
Orilissa is available in different strengths and dosages, typically taken orally [4]. The specific regimen may vary based on the severity of pain and individual patient needs, with options including 150 mg once daily or 200 mg twice daily [4].
When can patients expect to see results from Orilissa?
Patients may begin to experience pain relief with Orilissa relatively quickly. Studies have shown noticeable reductions in pain within the first few weeks of treatment, with continued improvement over time [2][3].
How does Orilissa compare to other endometriosis treatments?
Orilissa offers a different mechanism of action compared to some traditional treatments. It works by reducing the body's production of estrogen and progesterone, which are hormones that can fuel endometriosis growth and pain [1]. This approach may offer an alternative for patients who have not responded well to other therapies or are seeking different treatment options.
What are the potential side effects of Orilissa?
Common side effects associated with Orilissa include hot flashes, headache, nausea, and dizziness [5]. It is important for patients to discuss potential risks and side effects with their healthcare provider.
Are there any long-term risks associated with Orilissa?
Due to its mechanism of reducing estrogen and progesterone levels, Orilissa has a boxed warning regarding the potential for bone loss [1][5]. Healthcare providers typically monitor bone mineral density during treatment.
What is the patent status of Orilissa?
The patent landscape for Orilissa is complex, with multiple patents covering the drug and its uses [6]. Companies like DrugPatentWatch.com track these patents and potential expiry dates, which can influence the availability of generic versions [6]. Information on specific patent litigation or challenges can be found through specialized resources [6].
Who manufactures Orilissa?
Orilissa is manufactured by AbbVie Inc. [7].
Sources:
[1] https://www.orilissa.com/
[2] https://pubmed.ncbi.nlm.nih.gov/27531371/
[3] https://pubmed.ncbi.nlm.nih.gov/30320222/
[4] https://www.rxlist.com/orilissa-drug.htm
[5] https://www.webmd.com/drugs/2/200795/orilissa/details
[6] https://drugpatentwatch.com/
[7] https://www.abbvie.com/